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brain volume loss associated with frank neuronal loss and FTD-like changes in social behaviour. These data are the first to
show neurodegeneration in mice expressing mutant CHMP2B and indicate that our mouse model is able to recapitulate neu-
rodegenerative changes observed in FTD. Neuroinflammation has been increasingly implicated in neurodegeneration, includ-
ing FTD. Therefore, we investigated neuroinflammation in our CHMP2B mutant mice. We observed very early microglial pro-
liferation that develops into a clear pro-inflammatory phenotype at late stages. Importantly, we also observed a similar
inflammatory profile in CHMP2B patient frontal cortex. Aberrant microglial function has also been implicated in FTD caused
by GRN, MAPT and C9orf72 mutations. The presence of early microglial changes in our CHMP2B mutant mice indicates neuro-
inflammation may be a contributing factor to the neurodegeneration observed in FTD.
Introduction
Frontotemporal dementia (FTD) is a common cause of young-
onset dementia. FTD is characterized by personality and behav-
ioural changes, or language impairment, due to atrophy of the
frontal and temporal lobes (1). In addition, FTD also shares a clin-
ical spectrum with amyotrophic lateral sclerosis (ALS), with both
diseases sharing common pathologies and genetic causes (2).
Familial FTD can be caused by mutations in a number of di-
verse genes. The most common causes of FTD are mutations in
the genes that encode C9orf72, tau (MAPT) and progranulin
(GRN), with less common causes identified as mutations in
valosin-containing protein, TDP-43 (TARDBP), fused in sarcoma
and charged multivesicular body protein 2B (CHMP2B) (3).
A mutation in CHMP2B was identified as the cause of an au-
tosomal dominant form of FTD, termed FTD-3 (4,5), which we
will refer to as CHMP2B-FTD. The location of the mutation in a
splice acceptor site results in the production of two variants of
C-terminally truncated CHMP2B proteins: CHMP2BIntron5 in
which the final 36 amino acids are replaced with a single valine
residue, or CHMP2BD10 in which the final 36 amino acids are
replaced with 29 nonsense residues (5). Further evidence that
C-terminal truncation of CHMP2B leads to FTD was found in a
subsequent study in a Belgian FTD cohort, where a distinct
truncation mutation CHMP2BQ165X that leads to the loss of the
final 49 amino acids was discovered (6,7).
The normal function of CHMP2B is as part of the endosomal
sorting complex required for transport III (ESCRT-III), which is
necessary for membrane deformation during intraluminal vesi-
cle biogenesis in the maturation of endosomes (8). Mature endo-
somes, or multivesicular bodies, ultimately fuse with lysosomes
to allow degradation of endosomal content (8,9). Alternatively,
MVBs can also fuse with autophagosomes, to form hybrid or-
ganelles known as amphisomes, prior to lysosomal fusion
(9,10). Mutant CHMP2BIntron5 has been shown to affect the matu-
ration of both endosomes and autophagosomes (11–14). We re-
cently reported in a CHMP2B mouse model of FTD that
expresses human CHMP2BIntron5 at endogenous levels, that both
neurons and microglia accumulate progressive and specific
lysosomal storage inclusions (15). Similar inclusions were also
identified in the frontal cortex of patients with CHMP2B-FTD
(15). Interestingly, a lysosomal storage disorder phenotype has
also been reported in patients and mouse models with GRN mu-
tations, suggesting some mechanistic overlap between GRN and
CHMP2B (16,17).
In addition to cell autonomous effects in neurons such as
endolysosomal dysfunction, there is increasing focus on the con-
tribution of microglia and neuroinflammation to the progression
of neurodegeneration. Neuroinflammation has been implicated
in the pathophysiology of neurodegenerative disease, including
Alzheimer’s disease, Parkinson’s disease, ALS (18) and FTD
caused by GRN mutations (19). Substantial evidence shows that
microglial cells participate in the progression of the
neurodegenerative process, and recent strategies aiming at in-
hibiting microglial proliferation have shown beneficial effects in
mouse models of prion disease (20), AD (21–23) and ALS (24). We
therefore performed a detailed characterization of the activation
and proliferation of microglia in conjunction with assessment of
brain volume, neuronal loss and longitudinal behavioural analy-
ses in our CHMP2B mutant mouse model. We show that micro-
glial activation is an early event in CHMP2B-FTD, which precedes
neuronal loss and behavioural defects. In addition, we report
that a similar microglial activation profile exists in CHMP2B-FTD
patient brain. These data implicate microglial activation as a po-
tential pathway for early therapeutic intervention.
Results
Volume loss in aged mutant CHMP2B mouse brain
For these studies, we utilized our CHMP2BIntron5 mice, which ex-
press mutant truncated human CHMP2BIntron5 at endogenous
levels (25). CHMP2BIntron5 mice were compared with mice over-
expressing wildtype human CHMP2B (CHMP2BWildtype) (25) and
non-transgenic controls. In order to investigate whether brain
atrophy occurs in CHMP2BIntron5 mice we used high resolution
ex vivo MRI to measure brain volume at 18 months of age. We fo-
cused on this late-stage time point to maximize the possibility
of detecting changes as behavioural impairments only become
apparent at 18 months of age (described below) and early time
points do not show overt inclusion pathology (25). We applied a
tensor-based morphometry map that does not require manual
delineation of regions of interest or isolation of specific
structures (26). This automated analysis revealed significant bi-
lateral volume loss in the thalamus and cortex of CHMP2BIntron5
mice compared with both non-transgenic (Fig. 1A) and
CHMP2BWildtype controls (Supplementary Material, Fig. S1) and
no significant difference between CHMP2BWildtype and non-
transgenic mice (not shown). We have shown previously that
these particular brain regions harbour inclusion pathology
(15,25), and these findings are consistent with brain volume
changes observed by MRI in CHMP2B-FTD patients (6,27,28), sug-
gesting that brain atrophy is occurring in CHMP2BIntron5 mice.
Neuronal loss in aged mutant CHMP2B mouse brain
In order to determine whether the observed volume loss in
CHMP2BIntron5 mice was due to loss of neurons, the brains that
had undergone MRI were serially sectioned and stereological
cell counts performed in the thalamus. Both the total cell num-
ber and the number of neurons were counted. The number of
neurons in the thalamus of CHMP2BIntron5 mice was found to be
significantly decreased compared with non-transgenic controls
(Fig. 1B), indicating that the volume loss observed by MRI was
due to loss of neurons. Interestingly, the total number of cells
was not significantly altered (Fig. 1B); this is likely to be due to
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the gliosis that we have previously reported in the thalamus of
CHMP2BIntron5 mice at 18 months of age (25). These data are the
first to show that endogenous expression levels of mutant
CHMP2BIntron5 can directly cause neuronal loss in vivo and indi-
cate that our model is faithfully recapitulating key neurodegen-
erative features of CHMP2B-FTD.
Social and motor deficits in aged mutant CHMP2B mice
Patients with FTD, including those with CHMP2B mutations, dis-
play changes in personality and behaviour as well as motor dys-
function (6,29); therefore behavioural testing was used to assess
disease-relevant deficits in the CHMP2BIntron5 mouse model at 6,
12 and 18 months of age compared with both non-transgenic
and CHMP2BWildtype controls. As this was the first behavioural
characterization of these transgenic lines, a battery of tests was
performed at each timepoint to facilitate interpretation of the
data. First, to assess exploratory behaviour, locomotor activity
was measured in an open field arena. Although there was no
difference in overall activity between any of the lines at each in-
dividual timepoint (Supplementary Material, Fig. S2A), examin-
ing time-bins across a single trial demonstrated that
CHMP2BIntron5 mice were significantly less active towards the
middle of the session at 18 months of age (Supplementary
Material, Fig. S2B). Analysis of the same open field data for
proportion of activity in the central zone did not show any dif-
ference between genotypes (Supplementary Material, Fig. S2C);
therefore, as a further measure of similar approach-avoidance
anxiety-like behaviour, mice were also analysed on an elevated
plus-maze, and no differences in time spent in the open
arms between genotypes was observed (Supplementary
Material, Fig. S2D).
Next, we assessed cognitive performance using tests of
short-term memory. In the short-term exploratory spatial mem-
ory tasks – spontaneous alternation and Y-maze spatial novelty
preference tests – mice of all genotypes performed well above
chance levels (Supplementary Material, Fig. S2E and F) with no
significant difference in their activity in the apparatus (data not
shown). Together, these data suggest that CHMP2BIntron5 mice do
not display anxiolytic phenotypes or behaviour indicative of dis-
inhibition or profound cognitive dysfunction.
We then examined motor coordination and grip strength us-
ing the accelerating rotarod and hanging grid tests. Interestingly,
18-month-old, but not 6- or 12-month-old CHMP2BIntron5 mice
performed significantly worse than non-transgenic and
CHMP2BWildtype mice in both of these tasks (Fig. 2A and B), dem-
onstrating that CHMP2BIntron5 mice develop late-onset motor de-
fects. In addition, we assessed depression-like behaviour in the
forced swim test and observed no difference between genotypes
at any timepoint (Supplementary Material, Fig. S2G).
Figure 1. Volume loss is accompanied by neuronal loss in 18-month-old CHMP2BIntron5 mouse brain. (A) High resolution ex vivo MRI results, showing statistically signifi-
cant FDR-corrected (q¼0.05) t-statistics overlaid on the group-wise registration average image, revealing local structural differences between the brains of the
CHMP2BIntron5 mice (n ¼ 9) relative to non-transgenic controls (n ¼ 10). Regions highlighted in red represent a volume decrease in the CHMP2BIntron5 brains, and regions
highlighted in blue represent a volume increase. Significant volume loss can be readily observed in the thalamus, cortex and brain stem of CHMP2BIntron5 brains.
Sagittal, coronal and horizontal views are shown. (B) Stereological cell counts reveal a significant decrease in neuron number in 18-month-old CHMP2BIntron5 thalamus
(n ¼ 5) when compared with non-transgenic control (n ¼ 5). There is no difference in the total number of cells in the thalamus. *P < 0.05, t-test. Data are shown as mean
6 SEM.
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We went on to examine sociability and preference for social
novelty in CHMP2BIntron5 mice using a modified three chamber
assay. Briefly, in the habituation stage (stage 1), the test mouse
was allowed to explore all three chambers of the apparatus.
In stage 2 (testing for sociability), an unfamiliar stranger mouse
enclosed in a wire cage was placed in either the left or right
chamber, and the test mouse was allowed to freely explore all
chambers. CHMP2BIntron5 mice spent the same amount of time
interacting with the stranger mouse as the non-transgenic and
CHMP2BWildtype mice at 6, 12 and 18 months of age, demonstrat-
ing that no specific defect in sociability occurs in these lines dur-
ing ageing (Fig. 2C). In stage 3 of the test the preference for social
novelty was analysed, with stranger 1 retained in its original po-
sition, and a novel unfamiliar mouse (stranger 2) introduced to
the opposite chamber. Interestingly, at 18 months of age, but not
earlier timepoints, CHMP2BIntron5 mice spent significantly less
time interacting with stranger 2, demonstrating a decreased in-
terest in novel social interaction (Fig. 2D). These data were cor-
roborated by quantification of the time spent in each chamber of
the apparatus (Supplementary Material, Fig. S3 A–C). This appar-
ent lack of interest in novel social interaction was not due to de-
fects in olfaction, as the olfactory response of the CHMP2BIntron5
mice to both attractive and aversive scents was normal in these
animals (Supplementary Material, Fig. S3D). In summary, these
data show specific FTD-like changes in social behaviour and
late-onset motor deficits in CHMP2BIntron5 mice.
Early and progressive neuroinflammatory reaction in
mutant CHMP2B mouse brain
Having determined that expression of CHMP2BIntron5 leads
to neuronal loss and behavioural changes at late stages
(18 months) in our mouse model, we next sought to determine
whether neuroinflammation contributes to this process. We
therefore looked for early microglial changes at 3 months of
age. We assessed the number of microglial cells present in dif-
ferent brain regions of 3-month-old non-transgenic,
CHMP2BWildtype and CHMP2BIntron5 mice. Results showed a sig-
nificant increase in the number of microglia (Iba-1þ) both in the
thalamus and hippocampus of CHMP2BIntron5 mice compared
with non-transgenic and CHMP2BWildtype controls (Fig. 3A). We
then analysed the expression of well-known markers of micro-
glial proliferation at the same time point: components of the
Csf1/Csf1r signalling pathway, Cebpa and Pu.1 (20), but we ob-
served no significant changes in the mRNA levels of these
markers when we compared CHMP2BWildtype to CHMP2BIntron5
mice (Fig. 3B, upper panel). The expression of inflammatory cy-
tokines was also unaltered (Fig. 3B, lower panel).
At late stages of the disease (18 months), there was also a
significant expansion of the microglial population, with a 2- to
4-fold increase in the number of Iba-1þcells in the cortex, thala-
mus and hippocampus of CHMP2BIntron5 mice compared with
non-transgenic and CHMP2BWildtype mice (Fig. 4A). Analysis of
the microglial coverage of the cortex showed a 3- to 3.5-fold in-
crease in CHMP2BIntron5 when compared with non-transgenic
and CHMP2BWildtype mice, with no significant differences in the
microglial distribution across CHMP2BIntron5 cortical layers (LIII-
IV: 3.2 6 0.15; LV: 3.66 0.20; LVI: 3.3 6 0.62; mean 6 SEM). This
was coupled with a significant up-regulation of specific genes
known to be involved in the proliferation of these cells, includ-
ing Csf1, Csf1r, Pu.1 and Cebpa (20) (Fig. 4B, upper panel).
Increased microglial numbers were also associated with an ex-
acerbated inflammatory reaction in the brain of CHMP2BIntron5
mice, as shown by significantly high expression of the proin-
flammatory cytokines IL1b and TNFa both at mRNA and protein
level that was consistent in all the analysed regions (Fig. 4B
(lower panel) and C).
We observed association of apoptotic neurons (NeuNþwith
condensed chromatin) with activated microglial cells, which
were often found in close apposition or engulfing NeuN cells
Figure 2. Social behaviour and motor impairments in 18-month-old CHMP2BIntron5 mice. Longitudinal behavioural phenotyping was performed on CHMP2BIntron5,
CHMP2BWildtype and non-transgenic mice (n ¼ 12 per group) at 6, 12 and 18 months of age. (A) and (B) Performance on the accelerating rotarod (A) and the hanging grid
test (B) was significantly impaired in 18-month old CHMP2BIntron5 animals compared with non-transgenic and CHMP2BWildtype control mice. (C) and (D) In the social in-
teraction test, no deficits in sociability were identified (C), whereas in the social novelty section of the task (D), CHMP2BIntron5 mutants spent significantly less time with
the new intruder mouse (S2) at 18 months of age versus non-transgenic and CHMP2BWildtype animals, **P < 0.01, * P < 0.05; ANOVA with Bonferroni post-hoc test). Data
are shown as mean6 SEM.
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(Fig. 5), indicating a microglial reaction to neurodegeneration.
However, we did not observe microglial phagoptosis
(phagocytosis of endangered but alive neurons). These changes
were not detected in CHMP2BWildtype or non-transgenic mice
(Fig. 5).
Overall, these results show an early microglial reaction in
CHMP2BIntron5 mouse brain. This progresses to an overt micro-
gliosis characterized by a proinflammatory phenotype at late
stages of the disease, which likely contributes to the neurode-
generative process.
Figure 3. Early neuroinflammatory changes in CHMP2BIntron5 mouse brain. (A) Representative microphotographs and quantification of microglial cells (Iba-1) in cortex,
thalamus and hippocampus of 3-month-old non-transgenic, CHMP2BWildtype and CHMP2BIntron5 mice (n¼3 per group). Scale bar: 100 mm. Data are shown as
mean6SEM. *P < 0.05, **P < 0.01 versus both non-transgenic and CHMP2BWildtype. (B) Analysis of mRNA levels of microglial proliferation and inflammation associated
genes in cortex, thalamus and hippocampus of 3-month-old non-transgenic, CHMP2BWildtype and CHMP2BIntron5 mice (n ¼ 4 per group). Data are represented with a
colour code (blue to red) as fold change of CHMP2BWildtype vs. non-transgenic and CHMP2BIntron5 versus non-transgenic mice from 6 to 6.
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Spinal cord and muscle pathology in late stage
CHMP2BIntron5 mice
Given that CHMP2BIntron5 animals show motor deficits by the
end stage of the disease (Fig. 2A and B), we further explored the
alterations in the spinal cord and muscle of these mice at
18 months of age. There was a significant 2-fold increase in the
number of microglial cells (Iba-1þ) in CHMP2BIntron5 spinal cord
when compared with CHMP2BWildtype and non-transgenic mice
Figure 4. Late stage neuroinflammatory changes in CHMP2BIntron5 mouse brain. (A) Representative microphotographs and quantification of microglial cells (Iba-1) in
cortex, thalamus and hippocampus of 18-month-old non-transgenic, CHMP2BWildtype and CHMP2BIntron5 mice (n ¼ 3 per group). Scale bar: 100 lm. Data are shown as
mean6SEM. *P < 0.05, **P < 0.01, ***P < 0.001 versus non-transgenic. (B) Analysis of mRNA levels of microglial proliferation and inflammation associated genes in cor-
tex, thalamus and hippocampus of 18-month-old non-transgenic, CHMP2BWildtype and CHMP2BIntron5 mice (n ¼ 4 per group). Data are represented with a colour code
(blue to red) as fold change of CHMP2BWildtype versus non-transgenic and CHMP2BIntron5 versus non-transgenic from 6 to 6. *P < 0.05, **P < 0.01, ***P < 0.001 versus
CHMP2BWildtype. (C) Protein analysis of cortical samples showing a significant overexpression of proinflammatory cytokines (n ¼ 4 per group). Data are shown as
mean6SEM. *P < 0.05, ***P < 0.001 versus both non-transgenic and CHMP2BWildtype.
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(Fig. 6). We also performed fibre type analysis in quadriceps
muscles as changes in fibre type composition, such as an in-
crease in type IIa fibres, can be indicative of denervation (30).
CHMP2BIntron5 mice had more type IIa fibres than
CHMP2BWildtype and non-transgenic mice (8.3 6 3.7, 1.7 6 1.2
and 4.2 6 1.9, respectively, mean 6 SEM), which reached sig-
nificance only for the comparison with CHMP2BWildtype
(Supplementary Material, Fig. S4), suggestive of denervation in
CHMP2BIntron5 mice. Therefore, alterations in both the spinal
cord and distal processes may contribute to the motor pheno-
types we observe.
Microglial activation in CHMP2B-FTD brain parallels late
stage CHMP2BIntron5 mouse brain
RT-PCR in CHMP2B patient frontal cortex showed a non-
significant trend towards a pro-inflammatory profile similar to
that in 18-month-old CHMP2BIntron5 mouse brain, although
there was a high level of variability across the genes tested
(Fig. 7A). We have previously shown that autofluorescent lyso-
somal storage-like pathology is a feature of the CHMP2B muta-
tion and is increased in microglia in CHMP2B patient frontal
cortex when compared with both neurodegenerative disease
and normal controls (15). A direct comparison between mouse
and human revealed activated microglia containing lysosomal
storage pathology that are strikingly similar in CHMP2BIntron5
mouse brain and CHMP2B patient frontal cortex (Fig. 7B). These
data suggest our CHMP2BIntron5 mice may provide an accurate
model of microglial activation during disease pathogenesis.
Discussion
Neurodegenerative conditions are often associated with a neuro-
inflammatory reaction characterized by the proliferation and acti-
vation of microglia (18). However, the exact contribution of this
gliosis to the progression of neurodegeneration in the disease pro-
cess is not well understood. The time-course of the onset of these
pathologies is difficult to dissect in patient samples, which by ne-
cessity are only examinable at the end stage of disease. In order to
better understand the temporal order of gliosis, neuronal loss and
onset of behavioural symptoms in FTD, we have investigated
these pathologies in detail in a mouse model of CHMP2B-FTD that
expresses endogenous levels of mutant CHMP2B.
Volume and neuronal loss in mutant CHMP2B mice
We report that mutant CHMP2BIntron5 mice have decreased
brain volume, due to neuronal loss, in the cortex and thalamus
at 18 months of age. These are areas that we have previously re-
ported as showing a significant burden of neuronal and micro-
glial autofluorescent aggregates (15). It is striking that the
thalamus is the most affected brain region in our mutant
CHMP2B mouse model. Mutant CHMP2B expression is driven by
the hamster prion protein gene promoter, which is known to
Figure 5. Microglial engulfment of dying neurons in aged CHMP2BIntron5 mouse brain. Confocal analysis of the association of microglia (Iba1þ, green) with neurons
(NeuNþ, red) in the thalamus of 18-month-old CHMP2BIntron5 mice. DAPI (blue) stains nuclei and is used to identify apoptotic cells (condensed chromatin). Arrowheads
indicate normal neuronal nuclei, stars indicate condensed neuronal nuclei characteristic of apoptosis, which are opposed by microglial processes. Scale bar represents
20mm.
Figure 6. Microgliosis in 18-month-old CHMP2BIntron5 mouse spinal cord. Representative microphotographs and quantification of microglial cells (Iba-1) in the anterior
horn of the spinal cord of 18-month-old non-transgenic, CHMP2BWildtype and CHMP2BIntron5 mice. Data are shown as mean6SEM. *P < 0.05 versus CHMP2BWildtype and
non-transgenic (n ¼ 3 per group). Scale bar: 100 mm.
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express in the thalamus (31,32), so this likely explains the thala-
mus pathology we observe. However, the pathology is more se-
vere than in other models which use the same promoter. For
instance, the Tg2576 transgenic mouse drives expression of mu-
tant APP using the same hamster prion protein gene promoter
(33) and there are no amyloid plaques in the thalamus even at
16 months of age, while several other brains regions have a sig-
nificant plaque load (34). This suggests that the thalamus may
be particularly sensitive to mutant CHMP2B, which is consistent
with several imaging studies that show the thalamus is affected
in FTD (35). Indeed, the thalamus is one of the earliest brain re-
gions affected in C9orf72 mutation carriers, up to 25 years before
expected symptom onset (36). Furthermore, the thalamus is
part of the salience network, which consistently shows de-
creased network connectivity in FTD (35). Interestingly, we also
detected brain regions with increased brain volume. The rea-
sons for this are unclear but could include compensatory mech-
anisms. For example, several groups have shown with MRI that
the default mode network has increased connectivity in FTD
and that this correlates with decreased connectivity in the sa-
lience network (35). It will therefore be interesting to investigate
network connectivity in our CHMP2B mutant mouse model in
future studies.
We observed microglia engulfing apoptotic neurons in the
thalamus but not healthy neurons at 18 months of age. This in-
dicates that while microglia in CHMP2BIntron5 mice are involved
in clearance of cellular debris, neuronal loss is not directly
caused by aberrant microglial phagocytosis of healthy or at risk
neurons, known as phagoptosis (37). This is the first report of
mutant CHMP2BIntron5 causing neurodegeneration in vivo.
Therefore, we provide the first direct link between
CHMP2BIntron5 and neuronal loss, the core feature of FTD.
Importantly, the neurodegeneration is caused by endogenous
expression levels of CHMP2BIntron5. This suggests the pheno-
types we observe accurately model the neurodegenerative pro-
cesses caused by mutant CHMP2B rather than being artefacts
caused by over-expression of a toxic protein.
Behavioural changes in mutant CHMP2B mice
One important feature of our CHMP2BIntron5 model is that the
endogenous expression level of the transgene facilitates both
the identification of bona fide presymptomatic features of
CHMP2B dysfunction in addition to the longitudinal analysis of
neuropathology and behaviour. Here, we report a very specific
Figure 7. Similar activated microglia profiles in CHMP2B patient brain and 18-month-old CHMP2BIntron5 mouse brain. (A) Analysis of mRNA levels of microglial prolifera-
tion and inflammation associated genes in the frontal cortex of CHMP2B-FTD (n ¼ 4) and age-matched controls (n ¼ 5), as performed for 18-month-old CHMP2BIntron5
mice (Fig. 4B). Data are represented with a colour code (blue to red) as fold change of CHMP2B-FTD versus age-matched controls from 3 to 3. (B) Representative images
of microglia (Iba1, green) in CHMP2B patient frontal cortex and CHMP2BIntron5 thalamus reveals activated microglia containing characteristic mutant CHMP2B lysoso-
mal storage-like autofluorescent pathology in both patient brain and mouse brain. Autofluorescence is pseudo-coloured in red, neurons (b-III tubulin, blue) are also
shown in the left-hand image and nuclei (DAPI, blue) are shown in the right-hand image). Scale bar represents 25 mm.
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and late-onset defect in preference for social novelty but not so-
ciability in our CHMP2BIntron5 mice. Interestingly, an impair-
ment in social novelty using the same behavioural paradigm
was reported in a mouse model expressing CHMP2BIntron5 under
the control of the CamKIIa promoter to induce forebrain-
specific expression at below endogenous levels (38). The identi-
fication of the same behavioural phenotype in two distinct
mouse models that do not use over-expression implies this is a
genuine effect of CHMP2BIntron5 to induce FTD-like behavioural
changes. Importantly, impairments in social functioning are a
key feature of FTD (39) and are prominent in FTD caused by
CHMP2B mutation (29). Impairment in the social novelty para-
digm is an indication of altered social functioning and has been
utilized across other FTD-relevant models (40). For example, re-
ductions in social interest and/or social novelty have been iden-
tified in two different progranulin (Grn)-deficient models (41,42).
Furthermore, alternative social interaction paradigms, such as
the resident-intruder test, are impaired in Grn mutant mice
(43,44). Interestingly, reducing inflammation in a Grn mouse
model can rescue social novelty defects (45) indicating that the
microgliosis we observe in mutant CHMP2B mice may contrib-
ute to the social novelty phenotype. Such social behaviours in
mice can be influenced by other physiological and environmen-
tal factors; importantly, here we did not observe any other
behavioural changes in a range of additional tests including
those for olfaction, novelty-induced locomotor activity, spatial
novelty preference or depression-like behaviour. This indicates
a very specific defect in social behaviour occurs in our
CHMP2BIntron5 model.
Furthermore, our CHMP2BIntron5 mice do not show behav-
iours indicative of anxiety. In contrast, other FTD-relevant
mouse studies report non-anxious phenotypes in approach-
avoidance paradigms, often cited as an indicator of
disinhibition-like behaviour. These findings are not universal,
however. Increased time in the open arms of an elevated plus-
maze is observed in certain Grn-deficient mutants (42),
tau-encoding MAPT transgenics (46,47) as well as the CamKIIa-
driven CHMP2B model (38). Yet a different Grn-deficient mutant
(43) and the recently described PLBtau model – a mutant that
expresses a single copy of human FTD-associated mutant tau –
both show heightened anxiety (48). Therefore, data from these
types of behavioural paradigms in the mouse needs to be inter-
preted with care and must be considered in context of the other
behavioural and neuropathological observations (40).
Finally, we also observed deficits in grip strength and motor
co-ordination at 18 months of age, indicating late-stage motor
deficits. These findings are consistent with motor-deficits in a
recently reported transgenic CHMP2BIntron5 mouse model that
drives expression using the neuronal Thy1.2 promoter (49), as
well as the presence of motor symptoms at late stages of dis-
ease in patients with CHMP2B-FTD (29). Importantly, these mo-
tor problems did not confound interpretation of the social
novelty data, as the distance travelled by CHMP2BIntron5 mice
during testing was unaffected. Furthermore, we observed equiv-
alent activity of CHMP2BIntron5 mice compared with control
groups in other apparatus (e.g. elevated plus maze, Y-maze and
T-maze) at 18 months of age. A slight reduction in activity was
noted in the open field (Supplementary Material, Fig. S2B), likely
a reflection of the motor dysfunction, although this was not ob-
served until 40 min into the test; notably, this is beyond the ex-
posure time in the apparatus used for the other behavioural
paradigms so would not affect these results. The motor changes
were accompanied by marked microgliosis in the spinal cord
and altered muscle fibre type composition at 18 months of age.
While not conclusive, these data are consistent with the
distal denervation reported in the Thy1.2 CHMP2B transgenic
model (49).
Microglial phenotypes in CHMP2B patient brain
We used RT-PCR to measure the expression levels of genes im-
plicated in inflammation in the frontal cortex of CHMP2B pa-
tients and age-matched controls. Our results show a trend
towards a proinflammatory profile, with a slight increase in
microglial proliferation pathways and proinflammatory cyto-
kines. However, no statistically significant changes were ob-
served so this alone cannot be viewed as evidence of a
microglial contribution for CHMP2B-FTD. Confounds such as
varying post-mortem delays and degrees of neuronal loss
across samples also make such data hard to interpret. We there-
fore also investigated microglia in CHMP2B patient brain using
immunohistochemistry. We identified microglia with striking
resemblance to those observed in late-stage 18-month-old mu-
tant CHMP2B mouse brain. In both cases, the microglia had an
enlarged activated appearance and were full of the dense
lysosomal-storage type aggregates we recently reported to be a
hallmark CHMP2B neuronal pathology (15). Intriguingly, the first
in-depth neuropathological description of CHMP2B-FTD (prior to
the identification of the CHMP2B mutation) noted the presence
of abnormal diffuse ubiquitin staining in microglia (29), which
may represent the pathology we observe here. This convergence
of end-stage microglial pathology in CHMP2B patient brain and
our CHMP2BIntron5 mouse model indicates that the earlier
microglial activation we observe in the mice may be relevant to
disease pathogenesis.
Microglial dysfunction in FTD
There are interesting parallels between FTD caused by CHMP2B
and GRN mutation. Both are characterized by lysosomal storage
pathology (15,50). We now report early microglial activation in
CHMP2B mutant mice that precedes neuronal loss and behav-
ioural changes. Similarly, microglia have been implicated in
FTD caused by GRN mutation. Microgliosis accompanied by
behavioural changes occurs in several different Grn homozy-
gous knockout (Grn -/-) mouse models (41,42,44,51). Reducing
aberrant microglial activity reduces behavioural changes
(52,45), suggesting microglia play an important role in neurode-
generation caused by progranulin deficiency. However, it is im-
portant to differentiate between heterozygous (Grnþ/-) and
homozygous (Grn -/-) knockout mice, as dosage-dependent ef-
fects cause distinct pathologies in human patients. Individuals
homozygous for GRN mutations present with neuronal ceroid
lipofuscinosis (NCL), a form of lysosomal storage pathology,
whilst heterozygous Grn mutations result in FTD (17,53).
Interestingly, a comparison of Grnþ/- mice to Grn -/- mice,
found no gliosis in the heterozygous Grn state at 12 months, al-
though the heterozygous animals do show sociability defects
from 6 to 7 months of age (41). Thus in this Grnþ/- mouse model
overt microgliosis does not appear to play a role in producing at
least some FTD-like behavioural changes.
Reducing microglial activation has also been reported to re-
duce tau pathology and neurodegeneration in the rTg4510
transgenic tau model of FTD (54). In addition, C9orf72 knockout
mice have impaired macrophage and microglial function char-
acterized by a proinflammatory phenotype (55). While loss of
C9orf72 is not generally considered the major driver of disease
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(56), loss of function and microglial alterations could well con-
tribute to disease progression. In addition, mutations in the
microglial gene TREM2 have been identified in FTD cases (57)
and cause altered microglial function (58). Therefore, there is
evidence that microglia may play a role in several different ge-
netic forms of FTD.
Neuroinflammation has been implicated in Alzheimer’s dis-
ease, Parkinson’s disease and amyotrophic lateral sclerosis
(18,20). Recent genetic association studies performed in
Alzheimer’s disease suggest that neuroinflammation is not sim-
ply a consequence of emerging pathological events associated
with degeneration, but instead a driver of pathology (59,60). Our
observation of an early neuroinflammatory component demon-
strated by increased numbers of microglial cells prior to behav-
ioural signs or neuronal loss, points to a potential role of
neuroinflammation in driving CHMP2B pathology. Strategies
aimed at inhibiting microglial proliferation produce beneficial
effects in mouse models of neurodegenerative diseases
(20,22,24). Taken all together, the modulation of neuroinflam-
mation emerges as a potential candidate for tackling FTD.
Materials and Methods
Mice
The mutant CHMP2BIntron5 expressing mouse line Tg153 was
used and maintained as a homozygous line as previously de-
scribed (15,25). Maintenance as a homozygous line precludes
comparison to non-transgenic littermate controls. Therefore,
Tg153 mice were compared with the full length human
CHMP2BWildtype mouse line Tg168, which was maintained as a
hemizygous line and Tg168 non-transgenic littermates, as previ-
ously described (15,25). Tg153 and Tg168 lines were backcrossed
to C57BL/6J for 10 generations to ensure matched genetic back-
ground. Tg153 mice were then interbred for either one or two
generations prior to initiating behavioural experiments.
Cases
Brain specimens (described in Supplementary Material, Table
S1) were obtained from the Queen Square Brain Bank for
Neurological Disorders, UCL Institute of Neurology and the
Frontotemporal Dementia Research in Jutland Association. The
study was approved by the UCL Institute of Neurology and
National Hospital for Neurology and Neurosurgery Local
Research Ethics Committee.
Immunohistochemistry
Mouse brains and spinal cords were immersion fixed in 10%
buffered formal-saline, embedded in paraffin wax and sections
cut at 3–4 lm thickness. Immunohistochemistry was previously
described (15). Immunohistochemistry was performed as previ-
ously described (15,20). Sections were processed for dewaxing,
and antigen retrieval was performed with boiling citrate buffer
(pH 6.0) for 20 min. Sections were treated with 1% metha-
nolþ 30% H2O2 to block for endogenous peroxidase activity
(only for bright field immunohistochemistry), and with 5% nor-
mal serumþ 0.1% BSA for nonspecific binding. After rinses with
PBS-0.1% Tween 20 (PBST), sections were incubated overnight at
4 C with rabbit anti-Iba1 (Wako, 019-19741) and mouse anti-
NeuN (Millipore, MAB377). For immunofluorescence, sections
were incubated in Sudan Black in 70% EtOH for 10 min in order
to reduce autofluorescence of the tissue. After washes with
PBST, sections were incubated with the appropriated biotiny-
lated (Vector Labs) or Alexa 488- and 594-conjugated secondary
antibodies (Invitrogen). For bright field immunohistochemistry,
following rinses sections were incubated with Vectastain ABC
complex (Vectors Labs) and visualized with diamino-benzidine
(DAB) precipitation. Sections were mounted with DePeX and im-
aged in a Leica DM5000B microscope, coupled to a Leica
DFC300FX camera. For immunofluorescence labelling, nuclei
were counterstained with DAPI and mounted with Mowiol/
DABCO (Sigma-Aldrich) mixture. Sections were visualized on a
Leica TCS-SP5 confocal system, coupled to a Leica CTR6500
camera. Quantification of microglial cells (n ¼ 3 per group) was
performed from the cortex, thalamus and CA1 of the hippocam-
pus, and represented as cells per square millimetre. Visual in-
spection of 3 mice of each genotype was used to identify DAPI
condensation.
For Figure 7 only, Iba1 and b-III tubulin staining were per-
formed as previously described (15) on three 18-month-old
mouse brains and the frontal cortex of two CHMP2B-FTD patient
brains (Iba1 staining only). Alexa Fluor conjugated secondary
antibodies (Life Technologies) were used to visualize the stain-
ing. Images were collected using a 63 lens with a 1.4 NA on a
Zeiss LSM 510 confocal microscope; autofluorescence was iden-
tified by its presence in all channels.
RT-PCR
Mouse cortex, thalamus and hippocampus were dissected from
female non-transgenic, CHMP2BWildtype and CHMP2BIntron5 brains
under a microscope. Samples were homogenized in Trizol re-
agent (Invitrogen), following the manufacturer instructions to
isolate RNA, as previously described (20). The isolated RNA was
quantified (Nanodrop, Thermo Scientific) and retrotranscribed
with iScirptTM cDNA Synthesis Kit (Biorad). cDNA libraries were
analysed by RT-PCR using iTaqTM Universal SYBRVR Green
Supermix (Biorad) for the following genes (Sigma-Aldrich): Csf1
(NM_007778.4; forward (FW), agtattgccaaggaggtgtcag; reverse
(RV), atctggcatgaagtctccattt), Csf1r (NM_001037859.2; FW, gcag-
taccaccatccacttgta; RV, gtgagacactgtccttcagtgc), Il34 (NM_00113
5100.1; FW, ctttgggaaacgagaatttggaga; RV, gcaatcctgtagttgatggg-
gaag), Pu.1 (NM_011355.1; FW, cagaagggcaaccgcaagaa; RV,
gccgctgaactggtaggtga), Cebpa (NM_ 007678.3; FW, agcttacaacaggc-
caggtttc; RV, cggctggcgacatacagtac), Tgfb (NM_011577; FW:
tgtacggcagtggctgaacc, RV: cgtttggggctgatcccgtt), Il1b (NM_00836
1.3; FW, cagacccaccctgca; RV, accgtttttccatcttcttct), Tnfa (NM_013
693; FW: aggcactcccccaaaagatg, RV: ttgctacgacgtgggctac), Irf8
(NM_008320; FW: cggggctgatctgggaaaat, RV: cacagcgtaacctcg
tcttc), Il6 (NM_031168.1; FW, tccagaaaccgctatgaagttc; RV, caccag-
catcagtcccaaga), Ccl2 (NM_011333.3; FW: ttaaaaacctggatcggaac-
caa, RV: gcattagcttcagatttacgggt), Arg1 (NM_007482.3; FW, agcact
gaggaaagctggtc; RV, cagaccgtgggttcttcaca), Runx1 (NM_001111021;
RW: caggcaggacgaatcacact, RV: ctcgtgctggcatctctcat), Il4 (NM_021
283.2; FW, cctcacagcaacgaagaaca; RV, cgaaaagcccgaaagagtc) and
Gapdh (NM_008084.2; FW, tgaacgggaagctcactgg, RV, tccac-
caccctgttgctgta). Data were analysed by DDCt method, using
gapdh as a housekeeping gene.
Human frontal cortex RNA was extracted using QIAzol
(Qiagen) from CHMP2B-FTD (n¼ 4) and age-matched controls
(n¼ 5). Further details for each case are provided in
Supplementary Material, Table S1. RNA was retrotranscribed as
described above. cDNA libraries were analysed by RT-PCR using
iTaqTM Universal SYBRVR Green Supermix for the following genes
(Sigma-Aldrich): CSF1 (NM_000757.5; FW, agccacatgattgggagtgg;
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RV, tggatctttcaactgttcctggt), CSF1R (NM_005211.3; FW,
cctgggacccttttctgacc; RV, aggtgtgcctgtatgtgtcc), Il1B (NM_000576.
2; FW, ggctgctctgggattctcttc; RV, agtcatcctcattgccactgta), TNFA
(NM_000594.3: FW, tccccagggacctctctcta; RV, gagggtttgctacaa-
catggg), TGFB (NM_000660.5; FW, ggaaattgagggctttcgcc; RV,
cggtagtgaacccgttgatgt), IL6 (NM_000600.4; FW, ggcactggcagaaaa-
caacc; RV, accaggcaagtctcctcattg), IL10 (NM_000572.2; FW, cga-
gatgccttcagcagagt; RV, ggcaacccaggtaaccctta), IL34 (NM_152456.
2; FW, ttgtccctcttgaatgcccc; RV, gacggagctttgtttacagca), IL4 (NM_
000589.3; FW, ctttgctgcctccaagaacac; RV, ccaacgtactctggttggct),
ARG1 (NM_001244438.1; FW, aggaaagattcccgatgtgcc; RV, gtccacgt
ctctcaagccaa), RUNX1 (NM_001754.4; FW, ggtttcgcagcgtggtaaaa;
RV, gcactgtgggtacgaaggaa), IRF8 (NM_002163.2; FW, atcaaaag-
gagcccttcccc, RV, gggagaatgctgaatggtgc), CEBPA (NM_004364.4;
FW, tataggctgggcttcccctt; RV, agctttctggtgtgactcgg), CCL2 (NM_
002982.3; FW, tcccaaagaagctgtgatcttca; RV, tttgcttgtccaggtggtcc)
and gapdh (NM_002046.5; FW, tcggagtcaacggatttggt; RV,
ttcccgttctcagccttgac).
Protein analysis
Mouse cortical samples from wild type, CHMP2BWildtype and
CHMP2BIntron5 brains were homogenized in RIPA buffer (Thermo
Fisher) with protease inhibitors (EASYpack, Roche) and phos-
phatase inhibitors (PhosSTOP, Roche). Protein was quantified
using BCA assay (Thermo Fisher) following the manufacturer’s
instructions. Assessment of inflammatory cytokines was per-
formed using the V-PLEX Plus Proinflammatory Panel 1 Kit
(Meso Scale Discovery).
Magnetic resonance imaging (MRI)
Microscopic MRI was performed as previously described (26) on
female mice: 10 CHMP2BIntron5, 7 CHMP2BWildtype and 10 non-
transgenic controls. One CHMP2BIntron5 mouse was excluded
from the analysis due to the presence of a brain tumour identi-
fied by the MRI. Briefly, mice were perfusion-fixed with 10%
buffered formal-saline doped with 8 mM Gd-DTPA. After this,
mice were decapitated and skin, muscle, lower jaw, tongue, na-
sal bones and zygomatic arches removed, with the remaining
intact skulls post-fixed in 10% buffered formal-saline containing
8 mM Gd-DTPA at 4 C for 9 weeks before imaging. All imaging
was performed with a 9.4T VNMRS horizontal bore scanner
(Agilent Inc.). An imaging gradient set with a 60 mm inner diam-
eter (SGRAD 115/60/HD/S, Agilent Technologies UK Ltd.,
Berkshire, UK) was used. A 35L mm birdcage RF coil was em-
ployed for RF transmission and signal detection. Tuning and
matching of the coil was performed manually. Prior to imaging,
samples were removed from fixative and excess solution care-
fully blotted with a paper towel. They were then immersed in
Fomblin perfluoropolyether (type PFS-1, Solvay Solexis S.p.A.,
Bollate, Italy) in 50 ml plastic syringes (permitting three samples
to be imaged simultaneously) and immobilized with surgical
gauze. Samples were allowed to equilibrate for at least 2 h at
room temperature prior to imaging. Air bubbles in samples
were minimized by the equilibration time and gentle agitation
of the syringe. High resolution ex vivo structural images were ac-
quired using a three-dimensional (3D) gradient echo sequence
with the following parameters: Field-of-view ¼ 32 mm 
25 mm  25 mm; resolution¼ 40 lm  40 lm  40 lm; repeti-
tion time¼ 17 ms; echo time¼ 4.54 ms; flip angle¼ 51; aver-
ages¼ 6. Total imaging time was 11 h 36 min. Up to three
samples were acquired at a time.
MRI image analysis
Brain images were manually masked and cropped from
multiple-subject scans using ITK-Snap software (61) and ori-
ented to the same standard space. N3 bias correction was ap-
plied to correct image intensity non-uniformities (62). Brain
tissue was automatically separated from skull using a multi-
atlas parcellation approach, Similarity and Truth Estimation for
Propagated Segmentations (63,64), employing an external mouse
brain atlas database (65) and open-source registration and seg-
mentation software, NiftyReg and NiftySeg (available: http://cmic
tig.cs.ucl.ac.uk/research/software). To align equivalent anatomi-
cal regions between subjects, we performed group-wise registra-
tion of all brain images, using NiftyReg and 1 iteration rigid
registration, 4 iterations affine registration, and 20 iterations
non-rigid registration (66), with normalized mutual information
used as the similarity measure. Finally, we performed Tensor-
Based Morphometry (67), using the deformation fields generated
during registration. We found the Jacobian determinant at each
voxel, log-transformed these values, and smoothed with a 3D
Gaussian kernel (FWHM 0.16mm). We then used the general lin-
ear model to compare local volume differences between groups,
with brain volume, from the brain masks, used as a covariate.
Stereology tissue processing
Five CHMP2BIntron5 and five non-transgenic brains were cut hor-
izontally in 60 mm sections and all sections were mounted on
Superfrost plus object glasses (Thermo Scientific) in the order of
cutting. After drying the sections were stained with KaryoMAX
Giemsa Stain Solution (Life Technologies) for 20 min, destained
in 1% acetic acid for 30 min, dehydrated in series of baths of eth-
anol and xylene and cover slipped with DPX-mounting
medium.
Defining the region of interest for stereology
We used the MRI scans to identify the region of interest [the
thalamus was chosen as it had highly significant volume loss,
and is known to be affected in FTD (35)], and the mouse brain at-
las (Franklin and Paxinos, 3rd edition, 2007) to pinpoint specific
anatomical structures for delimiting the counting area. The re-
gion of interest was delimited at the front by the ventral hippo-
campal commissure, capsula interna and the reticular nucleus,
and at the back by a line going from the ‘anterior end’ of the
dentate gyrus to the midline. In the more ventral sections, this
line went in front of the Lithiod nucleus (when it became
visible).
Stereological cell counting
The total number of neurons in the thalamus was estimated us-
ing an unbiased stereological counting method as previously
described by West and colleagues (68) by a researcher blind to
mouse genotype. Briefly, using an Olympus BH2 microscope
controlled by CAST software (Olympus) the region of interest in
each section was marked at low magnification (2 objective).
Subsequently, neurons were counted using the 100 objective
by stepping through the region of interest with predetermined
steps in the x and y directions (300 mm in both directions) in a
raster pattern. Due to shrinkage of the tissue after drying and
dehydrating, the average tissue thickness was 12.67 mm, and we
therefore chose a dissector height of 8 mm, a counting frame
size of 240 mm2 and a section sampling fraction of 3 to obtain a
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sampling volume, at which we counted between 100 and 200
neurons in each animal. From these data, we calculated the to-
tal number of neurons in the thalamus of each animal. Neurons
were distinguished from other cell types as described by Hou
et al. (69).
Behavioural testing
Behavioural testing was carried out on female mice using co-
horts of 12 CHMP2BIntron5, 12 CHMP2BWildtype and 12 non-
transgenic controls. Female mice were used in order to keep the
cohort sex-matched and to reduce potential losses due to fight-
ing. Mice were analysed in parallel at 6, 12 and 18 months of age
in the order of tests as described below over an approximately
4-week period. One CHMP2BIntron5 mouse died prior to testing at
18 months of age. Mice were housed on a 12/12-h light/dark cy-
cle (lights on at 0700 h and off at 1900 h). Mice were housed in
groups of 3–4 with ad libitum food and water. All testing was per-
formed during the light phase. To avoid habituation to the test-
ing environment, different rooms were used for each paradigm
at each timepoint. All mice were weighed at monthly intervals
and no significant difference was observed between genotypes
at any timepoint (Supplementary Material, Fig. S3E). All behav-
ioural procedures were performed in accordance with the
United Kingdom Animals (Scientific Procedures) Act of 1986 and
the University of Oxford Policy on the Use of Animals in
Scientific Research. All experiments were approved by the
University of Oxford Animal Welfare and Ethical Review Board.
Locomotor activity
To measure novelty induced locomotor activity (LMA), experi-
ments were conducted in the light phase between 1200 and
1400 h. Ambulations were measured in transparent Plexiglass
cages (20 35 cm), equipped with infrared photobeams (San
Diego Instruments) over a total of 2 h.
Motor function
To test motor function, mice were placed on a grooved plastic
beam of a commercial rotarod device (Ugo Basile), which re-
volves at 5 rpm, facing in an orientation opposite to the rotation.
After 30 s, the speed of rotation was increased from 5 to 40 rpm
over 5 min. The time latency to fall from the rod or complete two
rotations on the rod without an attempt to run on the accelerat-
ing rod was recorded. Three single trials on consecutive days
were carried out. For grip strength analysis, mice were placed on
a wire mesh 40 cm2 and the grid was upturned so that the mouse
was hanging upside-down. The time taken for the mouse to fall
from the grid was recorded up to a maximum of 3 min.
Sociability and preference for social novelty behaviour
Sociability and preference for social novelty behaviour were as-
sessed based on a previously described method (70). The appa-
ratus was a rectangular, three-chambered arena (left and right
chambers 20 30 30 cm; centre chamber 20 20 30 cm; total
size 60 30 30 cm). Dividing walls were made from clear
acrylic, with small square openings (4 4 cm) allowing access
from the centre chamber into left and right chambers. Each
chamber was cleaned and fresh bedding added between trials.
A video camera, mounted in front of the apparatus, recorded
each session. The paradigm consisted of a three-stage
procedure. Stage (1) habituation: in the initial stage, the test
mouse was first placed in the centre chamber and allowed to
explore all three chambers of the apparatus for 5 min. It was
then replaced in the centre chamber for a further 5 min with ac-
cess to the left and right chambers denied by Plexiglasss doors.
Stage (2) sociability: an unfamiliar BALB/c mouse (Stranger 1:
weight- and sex-matched) was placed in either the left or right
chamber enclosed in a small, internal wire cage (10 cm diameter
 12 cm) which allowed nose contact but prevented fighting;
placement of Stranger 1 in the left or right chamber alternated
between trials, with an empty but otherwise identical wire cage
in the opposite chamber. Each stranger mouse had been habitu-
ated to placement in the small wire cage 24 h before testing.
Following placement of Stranger 1 into the left or right chamber,
both doors to these side chambers were then opened and the
test mouse was allowed to leave the centre chamber and ex-
plore all three chambers of the apparatus for 5 min. The test
mouse could therefore distribute its behaviour between the cen-
tre chamber, the chamber containing Stranger 1 or the opposite,
empty chamber. Time spent in each compartment was re-
corded, with entry into any chamber defined as all four paws in
that chamber. Stage 3) Preference for social novelty: each test
mouse was immediately returned to the centre chamber and
the doors to the side chambers were closed. Then followed a
second 5 min session to quantify social novelty preference to-
ward a novel stranger. With the initial stranger (Stranger 1; now
familiar) retained in its original chamber, a second, unfamiliar
mouse (Stranger 2) was placed in the previously empty but oth-
erwise identical small wire cage in the opposite chamber.
Following placement of Stranger 2 into the chamber opposite to
that still containing Stranger 1, both doors to the side chambers
were opened and the test mouse was allowed to leave the cen-
tre chamber and explore all three chambers of the apparatus for
a second period of 5 min; it could therefore distribute its behav-
iour between the centre chamber, the chamber containing the
previously investigated and now familiar mouse (Stranger 1)
and the opposite chamber containing the novel, unfamiliar
mouse (Stranger 2). All other parameters and measures were as
described above for Stage 2. All testing was counterbalanced for
left or right positioning of the stranger mice.
Olfactory Preference Test
As a measure of the sense of smell, olfactory response to both
attractive and aversive scents was assessed as previously de-
scribed (71).
Statistical Analysis
For immunohistochemistry, RT-PCR and protein analyses, data
are expressed as mean6SEM, and analysed using one-way
ANOVA, applying Tukey post hoc when necessary with Prism 6
(GraphPad) software. For stereological cell counts a t-test was
performed to compare cell numbers in CHMP2BIntron5 and non-
transgenic thalamus using Prism 5 (GraphPad). For behavioural
data, pairwise comparisons and interactions were performed us-
ing ANOVAs with additional post-hoc tests as stated. Analysis
was carried out using Prism 5 (GraphPad) or SPSS v.20 (IBM).
Supplementary Material
Supplementary Material is available at HMG online.
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